IRCT201601022394N19.

Trial name or title	Acronym: —
Methods	Type of trial: efficacy trial Allocation: randomised Intervention model: parallel Masking: double‐blinded Primary purpose: treatment
Participants	Condition: type 2 diabetes mellitus Enrolment: estimated 50 Inclusion criteria Diagnosis of type 2 diabetes for at least 2 years Willingness to participate BMI > 25 Between 45 and 70 years old Exclusion criteria Significant disease including cardiovascular, renal, or liver disease, or cancer Pregnancy Lactation Insulin use Weight and BMI change Consumption of nutritional supplements within past 8 weeks
Interventions	Intervention(s): resveratrol supplement (240 mg daily with lunch for 8 weeks) Comparator(s): placebo
Outcomes	Primary outcome(s): irisin, adiponectin Secondary outcome(s): fasting blood sugar (FBS), HbA1C, insulin
Starting date	Trial start date: June 2015 Trial completion date: not reported
Contact information	Responsible party/principal investigator: Shima Jazayeri, Iran University of Medical Sciences
Study identifier	Trial identifier:IRCT201601022394N19
Official title	Effects of resveratrol supplementation on serum irisin and adiponectin in patients with type 2 diabetes
Stated purpose of study	Quote: "to determine effects of resveratrol on serum irisin and adiponectin in patients with type 2 diabetes"
Notes